Welcome to our dedicated page for Allarity SEC filings (Ticker: ALLR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Allarity Therapeutics, Inc. SEC filings document the company’s clinical-stage oncology business, capital structure, governance, and material-event disclosures. The filings identify Allarity’s Nasdaq-listed common stock and emerging growth company status, and include 8-K reports covering Regulation FD presentations, scientific and clinical updates for stenoparib and the DRP® companion diagnostic, intellectual-property developments, operating and financial results, and promissory-note financing.
Proxy materials describe annual meeting matters and stockholder voting procedures, while material definitive agreement filings and other current reports provide formal disclosure on financing arrangements, corporate progress, and regulatory or clinical communications tied to Allarity’s precision oncology programs.
Allarity Therapeutics, Inc. entered into an amended and restated Management Services Agreement with Ljungaskog Consulting AB, the firm of CEO Thomas H. Jensen, effective June 1, 2026. The agreement fully replaces the prior 2024 management services arrangement.
The consultant’s 2026 base compensation will be paid 80% in Swedish Krona and 20% in U.S. dollars, equal to SEK 6,000,000 and US$163,043. The prior one-time US$100,000 signing bonus is removed. Annual bonus metrics are to be set each year, with any bonus capped at 60% of fees paid and, if earned, payable by March 15 following year-end.
For a termination by the company for convenience, the notice period increases from 15 to 30 days and the consultant becomes eligible for a termination payment equal to 12 months of the monthly fee, in addition to accrued amounts, subject to conditions such as a release and cooperation. Upon a termination by the consultant for Good Reason, severance increases from nine months to 12 months of the monthly fee on similar conditions. The agreement also adds provisions addressing Sections 409A and 280G of the U.S. Internal Revenue Code when applicable.
Allarity Therapeutics, Inc. reported a net loss of $2.8 million for the three months ended March 31, 2026, on minimal license revenue of $0.025 million. Research and development expenses were $1.3 million and general and administrative expenses were $1.4 million, both modestly lower than a year earlier.
Cash, cash equivalents and restricted cash totaled $29.8 million as of March 31, 2026, supported by $20.0 million of new promissory notes and a $6.0 million common stock purchase agreement with Tumim Stone Capital LLC. The company repurchased 264,000 shares for $0.3 million under its share repurchase plans and believes existing capital will fund operations for at least the next twelve months while it advances its lead cancer candidate stenoparib.
Jensen Thomas reported acquisition or exercise transactions in this Form 4 filing.
Allarity Therapeutics CEO Thomas Jensen received an equity grant of 200,000 shares of common stock as a compensation award. These shares are in the form of restricted stock units granted under the company’s Amended and Restated 2021 Equity Incentive Plan and were awarded at no cash cost per share.
The RSUs will vest in three equal annual installments on the first, second, and third anniversaries of the January 28, 2026 grant date, if he continues his relationship with the company through each vesting date. After this grant, Jensen holds 596,734 common shares directly.
Allarity Therapeutics director Jesper Hoeiland was granted equity compensation. The Form 4 reports an acquisition of 25,000 shares of Common Stock at a stated price of $0.00 per share, bringing his direct holdings to 25,000 shares after the transaction.
According to a footnote, these shares reflect restricted stock units granted pursuant to Allarity Therapeutics, Inc.'s Amended and Restated 2021 Equity Incentive Plan, which vested in full on the grant date. This filing reflects a compensation-related award rather than an open-market trade.
Allarity Therapeutics filed an initial ownership report for director Jesper Hoeiland. This Form 3 identifies Hoeiland as a director of Allarity Therapeutics, Inc. and serves as his initial statement of beneficial ownership in the company’s securities. The filing does not list any reportable transactions or derivative positions at this time.
Allarity Therapeutics, Inc. furnished an investor presentation and announced a speaking engagement by its CEO under a current report. The materials focus on stenoparib, an oral dual inhibitor of PARP and the WNT/tankyrase pathway, and the company’s Drug Response Predictor (DRP®) companion diagnostic platform.
The presentation highlights Phase 2 monotherapy data in heavily pretreated, platinum-resistant ovarian cancer, where stenoparib given twice daily showed a reported median overall survival of 22 months and extended benefit in patients with higher stenoparib-DRP scores. Allarity also describes ongoing Phase 2 trials in ovarian cancer and relapsed small cell lung cancer, and notes that its CEO will present “Dual Inhibition of PARP and WNT” at Precision Medicine Forum Europe 2026 in Stockholm.
McLaughlin Gerald W. reported acquisition or exercise transactions in this Form 4 filing.
Allarity Therapeutics, Inc. director Gerald W. McLaughlin received a grant of 45,000 shares of common stock in the form of restricted stock units on January 28, 2026. These RSUs vested in full on the grant date, bringing his directly held position to 70,000 shares after the award.
Allarity Therapeutics, Inc. reports that its active pharmaceutical ingredient manufacturing campaign for stenoparib is progressing as planned, with completion expected no later than the third quarter of 2026 at a GMP-compliant contract manufacturer in Europe. This Phase 3-focused campaign is intended to secure drug supply to support a potential pivotal trial in advanced ovarian cancer following FDA Fast Track designation.
The company states that all manufacturing-related payments have been completed and that no additional cash outlays for this manufacturing campaign are anticipated. Ongoing Phase 2 trials in advanced ovarian cancer and relapsed small cell lung cancer continue to enroll patients, supported by Allarity’s DRP companion diagnostic approach.
Allarity Therapeutics, Inc. is asking stockholders to vote at its virtual 2026 annual meeting on June 26, 2026. Proposals include electing one Class I director, ratifying Wolf & Company as auditor for 2026, and an advisory say-on-pay vote on named executive officer compensation.
The company seeks approval to raise its 2021 Equity Incentive Plan share pool from 1,521,990 to 2,021,990 shares and to permit potential issuance of more than 19.99% of outstanding common stock under a $6,000,000 equity line with Tumim Stone Capital, subject to Nasdaq rules and ownership caps. Stockholders are also asked to approve an amendment adding Delaware-permitted officer exculpation and to authorize potential adjournment of the meeting to solicit additional proxies if needed.